Rincon Bio performs NCI-H1703 xenograft models to test efficacy of preclinical therapies. Please see below for additional information or to request a quote.
NCI-H1703 was derived from a stage 1 lung squamous cell carcinoma of a 54-year-old Caucasian male smoker.
Used in xenografts to test the efficacy of novel cancer therapeutics. Tumors develop after being injected into the flank of immunocompromised mice.
Rincon Bio Growth Curve
Cell Line: NCI-H1703
Mouse Strain: Nude
Positive Control: None
From implant to stratification: N/A
Cells Implanted per Animal: 4 million
WHY WORK WITH
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
Most efficacy studies can be initiated within two business days.
We love our clients! We are flexible and easy to work with. And we take a personal interest in our clients' studies.